These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 9260732

  • 61. Pharmacokinetics of anticonvulsants in pregnancy: alterations in plasma protein binding.
    Yerby MS, Friel PN, McCormick K, Koerner M, Van Allen M, Leavitt AM, Sells CJ, Yerby JA.
    Epilepsy Res; 1990 Apr; 5(3):223-8. PubMed ID: 2384078
    [Abstract] [Full Text] [Related]

  • 62. Atovaquone has no effect on the pharmacokinetics of phenytoin in healthy male volunteers.
    Davis JD, Dixon R, Khan AZ, Toon S, Rolan PE, Posner J.
    Br J Clin Pharmacol; 1996 Aug; 42(2):246-8. PubMed ID: 8864327
    [Abstract] [Full Text] [Related]

  • 63. Benefits of a clinical pharmacokinetic service in optimising phenytoin use in the western Cape.
    Valodia P, Seymour MA, Kies BM, Folb PI.
    S Afr Med J; 1998 Jul; 88(7):873-5. PubMed ID: 9698715
    [Abstract] [Full Text] [Related]

  • 64. Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.
    Chaudhary N, Kabra M, Gulati S, Gupta YK, Pandey RM, Bhatia BD.
    BMC Pediatr; 2016 May 14; 16():66. PubMed ID: 27179628
    [Abstract] [Full Text] [Related]

  • 65. Population pharmacokinetics of phenytoin from routine clinical data in Japan.
    Yukawa E, Higuchi S, Aoyama T.
    J Clin Pharm Ther; 1989 Feb 14; 14(1):71-7. PubMed ID: 2921305
    [Abstract] [Full Text] [Related]

  • 66. Population pharmacokinetics of phenytoin from routine clinical data in Japan: an update.
    Yukawa E, Higuchi S, Aoyama T.
    Chem Pharm Bull (Tokyo); 1990 Jul 14; 38(7):1973-6. PubMed ID: 2268899
    [Abstract] [Full Text] [Related]

  • 67. Differential kinetics of phenytoin in elderly patients.
    Bachmann KA, Belloto RJ.
    Drugs Aging; 1999 Sep 14; 15(3):235-50. PubMed ID: 10503815
    [Abstract] [Full Text] [Related]

  • 68. Determination of enzyme or binding constants using generalized linear models, with particular reference to Michaelis-Menten models.
    van Belle G, Leurgans S, Friel P, Guo SW, Yerby M.
    J Pharm Sci; 1989 May 14; 78(5):413-6. PubMed ID: 2746480
    [Abstract] [Full Text] [Related]

  • 69. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
    Fischer JH, Patel TV, Fischer PA.
    Clin Pharmacokinet; 2003 May 14; 42(1):33-58. PubMed ID: 12489978
    [Abstract] [Full Text] [Related]

  • 70. Comparison of in vitro and in vivo developmental toxicity and pharmacokinetics of phenytoin in the rat.
    Beekhuijzen ME, Verhoef A, Klaassen R, Rompelberg CJ, Piersma AH.
    Pharmacol Toxicol; 2000 Aug 14; 87(2):96-102. PubMed ID: 10989948
    [Abstract] [Full Text] [Related]

  • 71. Phenytoin dosage individualization--five methods compared in the elderly.
    Hudson SA, Farquhar DL, Thompson D, Smith RG.
    J Clin Pharm Ther; 1990 Feb 14; 15(1):25-34. PubMed ID: 2318914
    [Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73. Phenytoin dosage requirements and pharmacokinetic variables.
    Taylor JW, Murphy MJ, Berg MJ, Perry PJ, Lyon LW, Ludden TM.
    Clin Pharm; 1983 Feb 14; 2(3):253-7. PubMed ID: 6883953
    [Abstract] [Full Text] [Related]

  • 74. Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects.
    Spaans E, van den Heuvel MW, Schnabel PG, Peeters PA, Chin-Kon-Sung UG, Colbers EP, Sitsen JM.
    Eur J Clin Pharmacol; 2002 Sep 14; 58(6):423-9. PubMed ID: 12242602
    [Abstract] [Full Text] [Related]

  • 75. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery.
    Wilder BJ, Campbell K, Ramsay RE, Garnett WR, Pellock JM, Henkin SA, Kugler AR.
    Arch Neurol; 1996 Aug 14; 53(8):764-8. PubMed ID: 8759983
    [Abstract] [Full Text] [Related]

  • 76. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate.
    Battino D, Estienne M, Avanzini G.
    Clin Pharmacokinet; 1995 Nov 14; 29(5):341-69. PubMed ID: 8582119
    [Abstract] [Full Text] [Related]

  • 77. Drug-drug interactions among drugs prescribed for nontuberculous mycobacterial infection and epilepsy: A case report.
    Yoshikawa N, Tazaki T, Hatanaka M, Oda Y, Matsumoto N, Sonoda J, Ikeda R.
    J Clin Pharm Ther; 2019 Feb 14; 44(1):119-121. PubMed ID: 30311244
    [Abstract] [Full Text] [Related]

  • 78. Clinical evaluation of plasma free phenytoin measurement and factors influencing its protein binding.
    Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Okuda M.
    Biopharm Drug Dispos; 2006 Mar 14; 27(2):77-84. PubMed ID: 16308884
    [Abstract] [Full Text] [Related]

  • 79. Nimodipine restores the altered hippocampal phenytoin pharmacokinetics in a refractory epileptic model.
    Höcht C, Lazarowski A, Gonzalez NN, Auzmendi J, Opezzo JA, Bramuglia GF, Taira CA, Girardi E.
    Neurosci Lett; 2007 Feb 14; 413(2):168-72. PubMed ID: 17240061
    [Abstract] [Full Text] [Related]

  • 80. Michaelis-Menten pharmacokinetics of phenytoin in adult Malaysian patients.
    Ismail R, Rahman AF.
    J Clin Pharm Ther; 1990 Dec 14; 15(6):411-7. PubMed ID: 2089048
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.